Impax Pharmaceuticals (NASDAQ:IPXL) is to reveal details of its recent clinical trials for the Parkinson's disease treatment Rytary. The unveiling will occur on March 18 at the American Academy of Neurology conference in San Diego. The company has conducted phase III and open-label extension trials for the drug.

Impax describes Rytary as a "formulation of cabidopa-levodopa for the treatment of idiopathic Parkinson's disease."

The company has had its difficulties lately, with the Food and Drug Administration raising numerous points of concern about its Hayward, California facilities in the regulator's findings of the firm's pre-approval and good manufacturing practices.